美国食品和药物管理局批准摘要:在手术后治疗IDH突变的2级星细胞瘤或Oligodendroglioma
Michael I Barbato1, Amy K Barone2, Stephanie L Aungst2
1United States Food and Drug Administration, Silver Spring, United States.
概括
沃拉西丁尼目前已获得FDA批准,用于治疗IDH突变的2级星细胞瘤和寡质瘤. 这种向治疗可显著延缓这些罕见脑癌患者的瘤进展.
科学领域:
- 神经瘤学
- 分子向治疗
- 临床试验研究
背景情况:
- 具有IDH突变的2级星细胞瘤和寡质瘤是罕见的脑瘤.
- 目前对这些质瘤的治疗选择有限,特别是在最初的手术切除后.
- 针对性治疗为改善这些患者的治疗结果提供了一个有希望的途径.
研究的目的:
- 评估沃拉西代尼布在IDH突变2级质瘤患者中的疗效和安全性.
- 为了比较弗拉西迪尼和安慰剂之间的无进展生存期 (PFS).
- 确定沃拉西登尼作为针对这一特定患者群体的治疗选择.
主要方法:
- 一个随机的,多中心的,双盲的试验比较沃拉西代尼与安慰剂.
- 使用盲目独立中央审查 (BICR) 和RANO-LGG标准评估无放射性进展生存期 (PFS).
- 包括成年人和儿童 (12岁及以上) 患有IDH突变的2级星细胞瘤或小细胞瘤.
主要成果:
- 与安慰剂相比,沃拉西代尼比在PFS中表现出显著的改善.
- 对于PFS的危险比 (HR) 为0. 39 (95% CI:0. 27,0. 56;p值< 0. 0001).
- 常见的副作用包括疲劳,头痛和恶心.
结论:
- 沃拉西丁尼是FDA批准的第一个针对IDH突变二级质瘤的向治疗.
- 在这种患者群体中,该药物显著延迟了放射性进展.
- 由于其长期的自然病史,PFS是评估低度质瘤治疗疗效的有效终点.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K